XNAS · Healthcare · Biotechnology
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -2.87 | -2.36 | +17.77% | $0 | ✅ Beat | -1.36% | +0.99% | — |
| 2026-03-03 | Q4 2025 | -2.55 | -4.09 | -60.39% | $0 | ❌ Miss | -4.10% | +6.38% | +1.00% |
| 2025-11-10 |
| Q3 2025 |
| -2.84 |
| -2.44 |
| +14.08% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -1.72 | -2.96 | -72.09% | $0 | ❌ Miss | -3.73% | +23.44% | +24.24% |
| 2025-03-04 | Q4 2024 | -0.24 | -0.20 | +16.67% | $0 | ✅ Beat | +10.53% | -2.87% | -16.53% |
| 2024-11-13 | Q3 2024 | -0.23 | -0.31 | -34.78% | $0 | ❌ Miss | +1.41% | -11.74% | +30.41% |
| 2024-05-14 | Q1 2024 | -0.36 | -0.30 | +16.67% | $0 | ✅ Beat | -3.40% | -3.40% | -19.25% |
| 2024-03-04 | Q4 2023 | -0.40 | -0.30 | +25.00% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.